Back to top
more

ANI Pharmaceuticals (ANIP)

(Delayed Data from NSDQ)

$64.95 USD

64.95
82,928

-0.48 (-0.73%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $64.94 -0.01 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales

by Zacks Equity Research

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.

BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the first quarter of 2024, while revenues slightly miss the mark. The company maintains revenue guidance for 2024.

Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat

by Zacks Equity Research

Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.

Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake

by Zacks Equity Research

Biogen's (BIIB) first-quarter earnings beat estimates but sales miss the mark. While sales of key drugs like Tecfidera, Tysabri & Spinraza declined, the company's cost-saving efforts show promise.

Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study

by Zacks Equity Research

Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing's syndrome.

Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study

by Zacks Equity Research

Sanofi's (SNY) BTK inhibitor, rilzabrutinib, demonstrates durable platelet response in the phase III LUNA 3 study in adult patients with immune thrombocytopenia.

Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?

by Zacks Equity Research

Alkermes (ALKS) expects its set of proprietary products, Vivitrol, Aristada and Lybalvi, to generate incremental sales and combat stiff competition in 2024.

Roche (RHHBY) Alecensa Wins FDA Nod for Label Expansion

by Zacks Equity Research

Roche (RHHBY) has won FDA approval for Alecensa as an adjuvant treatment, following tumor resection for patients with ALK-positive non-small cell lung cancer.

Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal

by Zacks Equity Research

Data from a mid-stage study show that Sage's (SAGE) experimental oral drug failed to show a statistically significant difference in treating patients with Parkinson's disease compared with a placebo.

Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up

by Zacks Equity Research

Vanda's (VNDA) board of directors unanimously rejects takeover proposals from Future Pak to acquire all outstanding shares of Vanda. Shares rise on the news.

GSK Announces FDA Acceptance of New Meningococcal Jab BLA

by Zacks Equity Research

The approval of GSK's 5-in-1 meningococcal ABCWY vaccine candidate, MenABCWY, could provide the broadest meningococcal serogroup coverage and lead to simplified immunization.

Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why

by Zacks Equity Research

Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.

Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study

by Zacks Equity Research

Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.

Corcept (CORT) Completes Enrollment in Phase II ALS Study

by Zacks Equity Research

The phase II DAZALS study is evaluating Corcept's (CORT) dazucorilant for treating patients with amyotrophic lateral sclerosis. Enrollment in the study is already complete.

Neumora (NMRA) Down on FDA Clinical Hold on Neurology Drug

by Zacks Equity Research

The FDA places a clinical hold on Neumora's (NMRA) phase I study evaluating NMRA-266 for some types of neuropsychiatric disorders. Shares of the company fall on the news.

J&J (JNJ) Q1 Earnings Beat Estimates, Sales Miss, MedTech Soft

by Zacks Equity Research

J&J (JNJ) beats estimates for first-quarter earnings but misses the same for sales. It tightens its sales and earnings growth expectations for 2024.

Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug

by Zacks Equity Research

Novartis (NVS) announces encouraging data on Fabhalta from a phase III study for the treatment for the treatment of immunoglobulin A nephropathy, a heterogeneous, progressive, rare kidney disease.

Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why

by Zacks Equity Research

Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.

Janux (JANX) Rises Almost 50% in a Week on Buyout Rumors

by Zacks Equity Research

Janux (JANX) stock surges after some reports claim that the company is exploring opportunities for a potential sale following buyout offers from big pharma companies.

Why ANI (ANIP) is Poised to Beat Earnings Estimates Again

by Zacks Equity Research

ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

AstraZeneca's (AZN) Fasenra Gets FDA Nod for Asthma in Kids

by Zacks Equity Research

The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.

ANI Pharmaceuticals (ANIP) Stock Moves -0.13%: What You Should Know

by Zacks Equity Research

ANI Pharmaceuticals (ANIP) closed at $66.96 in the latest trading session, marking a -0.13% move from the prior day.

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

Syros (SYRS) Up on FDA Fast Track Tag for Tamibarotene in AML

by Zacks Equity Research

The FDA bestows a Fast Track Designation to Syros' (SYRS) pipeline candidate, tamibarotene, in combination with venetoclax and azacitidine to treat newly diagnosed acute myeloid leukemia. Stock rises.